SB-3CT
Based on 27 publication(s) in Google Scholar
SB-3CT is a potent and competitive matrix metalloproteinase MMP-2 and MMP-9 inhibitor with Ki values of 13.9 and 600 nM, respectively. SB-3CT has high selectivity for gelatinases. SB-3CT shows blood-brain barrier permeability and has neuroprotective effects and anticancer activity.
For research use only. We do not sell to patients.
- Purity: 99.84%
- CAS No.: 292605-14-2
- Formula: C15H14O3S2
- Molecular Weight:306.40
-
Storage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
CNS-Penetrant Compound Library
HY-L028
-
Differentiation Inducing Compound Library
HY-L038
-
Neuroprotective Compound Library
HY-L070
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Angiogenesis-Related Compound Library
HY-L088
-
Targeted Diversity Library
HY-L099
-
Human Metabolite Library
HY-L123
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Heterocyclic Compound Library
HY-L138
-
Pain-Related Compound Library
HY-L139
-
Protease Inhibitor Library
HY-L147
-
Highly Selective Inhibitors Library
HY-L158
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) SB-3CT
More- Science. 2018 Sep 28;361(6409):eaao4227. [Abstract]
- Cancer Cell. 2023 Apr 10;41(4):757-775.e10. [Abstract]
- Adv Sci (Weinh). 2026 Apr;13(24):e19500. [Abstract]
- J Neuroinflammation. 2025 Oct 11;22(1):230. [Abstract]
- Cancer Lett. 2019 Jun 28:452:38-50. [Abstract]
- Brain Behav Immun. 2026 Mar 27:136:106567. [Abstract]
- Biomed Pharmacother. 2024 Jun 27:177:117033. [Abstract]
- Oncogene. 2019 Apr;38(14):2565-2579. [Abstract]
- J Cell Biol. 2023 Nov 6;222(11):e202209114. [Abstract]
- Brain Pathol. 2025 Jun 7:e70022. [Abstract]
- JCI Insight. 2026 Jan 22;11(5):e195176. [Abstract]
- Eur J Pharm Sci. 2026 Aug 1:223:107578. [Abstract]
- Int Immunopharmacol. 2024 Jun 30:135:112290. [Abstract]
- Int Immunopharmacol. 2019 Jul:72:339-347. [Abstract]
- Int Immunopharmacol. 2019 Jul:72:243-251. [Abstract]
- Neuropharmacology. 2023 Mar 1:225:109382. [Abstract]
- Mol Neurobiol. 2024 Oct;61(10):8438-8453. [Abstract]
- J Inflamm Res. 2025 Jan 25:18:1191-1205. [Abstract]
- Mol Cell Probes. 2020 Apr;50:101498. [Abstract]
- Neuroscience. 2018 May 1:377:126-137. [Abstract]
- BMC Cardiovasc Disord. 2024 Jul 12;24(1):354. [Abstract]
- Neurosci Lett. 2021 Aug 10:759:136049. [Abstract]
- SSRN. 2025 Oct 15.
- bioRxiv. 2023 Dec 18.
- bioRxiv. 2023 Oct 7.
- Research Square Preprint. 2021 Nov.
- Research Square Preprint. 2020 Jun.
Customer Validation & Images
-
IF
-
WB
-
WB
Biological Activity
|
MMP-2 13.9 nM (Ki) |
MMP-9 600 nM (Ki) |
SB-3CT has shown efficacy in an animal model of severe traumatic brain injury (TBI). SB-3CT inhibits MMP-9 with an inhibition constant Ki of 400±15 nM[1].
Inhibition of PC3 tumor growth by SB-3CT could also be a direct consequence of reduced extracellular matrix degradation within the bone tissue by the tumor cells themselves and/or by osteoclasts. Indeed, SB-3CT treatment is associated with a reduced osteolytic response, indicating that SB-3CT helps to preserve bone integrity[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Five-week-old male C.B.-17.SCID mice[3]
-
Dosage:50 mg/kg
-
Administration:IP; every other day; five weeks
-
Result:Inhibited intraosseous growth of human PC3 cells within the marrow of human fetal femur fragments previously implanted in SCID mice.
Chemical Information
-
CAS No. 292605-14-2
-
Appearance Solid
-
Molecular Weight 306.40
-
Formula C15H14O3S2
-
Color White to pink
-
SMILES
O=S(CC1SC1)(C2=CC=C(OC3=CC=CC=C3)C=C2)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)
Publications (27)
-
Journal Impact Factor
-
Most Recent
-
Science
Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. [Abstract]2018 Sep 28;361(6409):eaao4227. PMID: 30262472 -
Cancer Cell
Neutrophil extracellular traps formed during chemotherapy confer treatment resistance via TGF-β activation. [Abstract]2023 Apr 10;41(4):757-775.e10. PMID: 37037615
SB-3CT purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2023 Apr 10;41(4):757-775.e10. [Abstract]
SB-3CT (MMP9 inh.; 50 mg/kg/day; i.v.; 2 weeks) counteracts NET(neutrophil extracellular trap)-mediated EMT(epithelial-mesenchymal transition) in mice.
-
Adv Sci (Weinh)
Diabetes Mellitus Facilitates Gallstone Formation Through CXCR2-NETs-Mediated Liver-Bile Barrier Damage. [Abstract]2026 Apr;13(24):e19500. PMID: 41698066 -
J Neuroinflammation
MMPs and NETs are detrimental in CNS-tuberculosis with MMP Inhibition in CNS-tuberculosis mice improving survival. [Abstract]2025 Oct 11;22(1):230. PMID: 41076519 -
Cancer Lett
Tumor targeting and microenvironment-responsive multifunctional fusion protein for pro-apoptotic peptide delivery. [Abstract]2019 Jun 28:452:38-50. PMID: 30904618 -
Brain Behav Immun
Dorsal root ganglion macrophages mediate osteoarthritis pain via disruption of sensory neuron perineuronal nets. [Abstract]2026 Mar 27:136:106567. PMID: 41905490 -
Biomed Pharmacother
2024 Jun 27:177:117033. PMID: 38941889 -
Oncogene
Resistance to Src inhibition alters the BRAF-mutant tumor secretome to promote an invasive phenotype and therapeutic escape through a FAK>p130Cas>c-Jun signaling axis. [Abstract]2019 Apr;38(14):2565-2579. PMID: 30531837 -
J Cell Biol
Matriptase drives dissemination of ovarian cancer spheroids by a PAR-2/PI3K/Akt/MMP9 signaling axis. [Abstract]2023 Nov 6;222(11):e202209114. PMID: 37737895 -
Brain Pathol
Targeting TRPV4 to restore glymphatic system function and alleviate cerebral edema in ischemic stroke. [Abstract]2025 Jun 7:e70022. PMID: 40481713 -
JCI Insight
LYVE1 ectodomain shedding blunts lymphatic transmigration and clearance of macrophages during kidney injury. [Abstract]2026 Jan 22;11(5):e195176. PMID: 41587141 -
Eur J Pharm Sci
Metabolic fate and oral dosing feasibility of the formyl peptide receptor 2 agonist WKYMVm: An integrated analytical and kinetic modeling approach. [Abstract]2026 Aug 1:223:107578. PMID: 42250780 -
Int Immunopharmacol
Anesthesia/surgery activate MMP9 leading to blood-brain barrier disruption, triggering neuroinflammation and POD-like behavior in aged mice. [Abstract]2024 Jun 30:135:112290. PMID: 38796964 -
Int Immunopharmacol
Pretreatment with resveratrol ameliorate trigeminal neuralgia by suppressing matrix metalloproteinase-9/2 in trigeminal ganglion. [Abstract]2019 Jul:72:339-347. PMID: 31009895 -
Int Immunopharmacol
Doxycycline alleviates paraquat-induced acute lung injury by inhibiting neutrophil-derived matrix metalloproteinase 9. [Abstract]2019 Jul:72:243-251. PMID: 31003001 -
Neuropharmacology
Reduced inhibitory and excitatory input onto parvalbumin interneurons mediated by perineuronal net might contribute to cognitive impairments in a mouse model of sepsis-associated encephalopathy. [Abstract]2023 Mar 1:225:109382. PMID: 36543316 -
Mol Neurobiol
AQP4 Endocytosis-Lysosome Degradation Mediated by MMP-9/β-DG Involved in Diabetes Cognitive Impairment. [Abstract]2024 Oct;61(10):8438-8453. PMID: 38512439 -
J Inflamm Res
The Upregulation of IL-1β Induced by Cisplatin Triggers PI3K/AKT/MMP9 Pathway in Pericytes Mediating the Leakage of the Blood Labyrinth Barrier. [Abstract]2025 Jan 25:18:1191-1205. PMID: 39911951 -
Mol Cell Probes
Lung resided monocytic myeloid-derived suppressor cells contribute to premetastatic niche formation by enhancing MMP-9 expression. [Abstract]2020 Apr;50:101498. PMID: 31891749
SB-3CT purchased from MedChemExpress. Usage Cited in: Mol Cell Probes. 2020 Apr;50:101498. [Abstract]
Expression of MMP-9 in circulating M-MDSCs from tumor bearing mice with or without stimulation of the MMP-9 inhibitor SB-3CT.
-
Neuroscience
Autophagy- and MMP-2/9-mediated Reduction and Redistribution of ZO-1 Contribute to Hyperglycemia-increased Blood-Brain Barrier Permeability During Early Reperfusion in Stroke. [Abstract]2018 May 1:377:126-137. PMID: 29524637
SB-3CT purchased from MedChemExpress. Usage Cited in: Neuroscience. 2018 May 1:377:126-137. [Abstract]
To confirm the critical role of MMP-2/-9 and autophagy in OGD/R induced ZO-1 redistribution and reduction, the effects of MMP-2/9 inhibitor (SB-3CT) and autophagy inhibitor (3-MA) are examined on the endothelial barrier function and ZO-1 degradation.
-
BMC Cardiovasc Disord
Sodium tanshinone IIA sulfonate protects vascular relaxation in ApoE-knockout mice by inhibiting the SYK-NLRP3 inflammasome-MMP2/9 pathway. [Abstract]2024 Jul 12;24(1):354. PMID: 38992615 -
Neurosci Lett
Enterovirus 71 infection induced Aquaporin-4 depolarization by increasing matrix metalloproteinase-9 activity. [Abstract]2021 Aug 10:759:136049. PMID: 34126180 -
-
-
-
-
Solvent & Solubility
DMSO : ≥ 50 mg/mL (163.19 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (8.16 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.16 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Lee M, et al. Water-Soluble MMP-9 Inhibitor Reduces Lesion Volume after Severe Traumatic Brain Injury. ACS Chem Neurosci. 2015 Oct 21;6(10):1658-64. [Content Brief]
[3]. Bonfil RD, et al. Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor. Int J Cancer. 2006, 118(11), 2721-2726. [Content Brief]
[4]. Cui J, et al. Inhibition of MMP-9 by a selective gelatinase inhibitor protects neurovasculature from embolic focal cerebral ischemia. Mol Neurodegener. 2012, 15, 7-21. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.2637 mL | 16.3185 mL | 32.6371 mL | 81.5927 mL |
| 5 mM | 0.6527 mL | 3.2637 mL | 6.5274 mL | 16.3185 mL | |
| 10 mM | 0.3264 mL | 1.6319 mL | 3.2637 mL | 8.1593 mL | |
| 15 mM | 0.2176 mL | 1.0879 mL | 2.1758 mL | 5.4395 mL | |
| 20 mM | 0.1632 mL | 0.8159 mL | 1.6319 mL | 4.0796 mL | |
| 25 mM | 0.1305 mL | 0.6527 mL | 1.3055 mL | 3.2637 mL | |
| 30 mM | 0.1088 mL | 0.5440 mL | 1.0879 mL | 2.7198 mL | |
| 40 mM | 0.0816 mL | 0.4080 mL | 0.8159 mL | 2.0398 mL | |
| 50 mM | 0.0653 mL | 0.3264 mL | 0.6527 mL | 1.6319 mL | |
| 60 mM | 0.0544 mL | 0.2720 mL | 0.5440 mL | 1.3599 mL | |
| 80 mM | 0.0408 mL | 0.2040 mL | 0.4080 mL | 1.0199 mL | |
| 100 mM | 0.0326 mL | 0.1632 mL | 0.3264 mL | 0.8159 mL |
Powered by Bioz